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Insight into the cellular fate and 
toxicity of aluminium adjuvants 
used in clinically approved human 
vaccinations
Matthew Mold, Emma Shardlow & Christopher Exley
Aluminium adjuvants remain the most widely used and effective adjuvants in vaccination and 
immunotherapy. Herein, the particle size distribution (PSD) of aluminium oxyhydroxide and aluminium 
hydroxyphosphate adjuvants was elucidated in attempt to correlate these properties with the 
biological responses observed post vaccination. Heightened solubility and potentially the generation of 
Al3+ in the lysosomal environment were positively correlated with an increase in cell mortality in vitro, 
potentially generating a greater inflammatory response at the site of simulated injection. The cellular 
uptake of aluminium based adjuvants (ABAs) used in clinically approved vaccinations are compared 
to a commonly used experimental ABA, in an in vitro THP-1 cell model. Using lumogallion as a direct-
fluorescent molecular probe for aluminium, complemented with transmission electron microscopy 
provides further insight into the morphology of internalised particulates, driven by the physicochemical 
variations of the ABAs investigated. We demonstrate that not all aluminium adjuvants are equal neither 
in terms of their physical properties nor their biological reactivity and potential toxicities both at the 
injection site and beyond. High loading of aluminium oxyhydroxide in the cytoplasm of THP-1 cells 
without immediate cytotoxicity might predispose this form of aluminium adjuvant to its subsequent 
transport throughout the body including access to the brain.
Aluminium based adjuvants (ABA) are included in human vaccinations to boost or potentiate the immune 
response, to the injected antigen1. Whilst a consensus upon the immunomodulatory mechanism of action of 
ABA has yet to be reached, it has become increasingly recognised that activation of the innate immune response 
is crucial for increased antibody titres1,2. The continued and widespread use of ABA has followed the emergence 
of recombinantly expressed protein antigens of high purity as a safer alternative to inactivated or attenuated 
pathogens2,3. Owing to the homogeneity and generally weak immunogenicity of recombinant antigens, the inclu-
sion of adjuvants is often necessary for the induction of robust immune responses and effective immunisation2,4. 
Furthermore, the use of adjuvants in human vaccinations has been linked to adverse effects5,6 often classified 
under Autoimmune (or autoinflammatory) syndrome induced by adjuvants (ASIA)7. Combined with the rela-
tively low cost of hydrated colloidal aluminium salts and their ease of inclusion as effective adjuvants within clin-
ically approved vaccine formulations, the continued use of ABA in human vaccinations is likely to continue1,2,4.
Of the most commonly used ABA in clinically approved vaccine formulations are the commercially available 
aluminium oxyhydroxide based, Alhydrogel® and aluminium hydroxyphosphate based, Adju-Phos®, adjuvants8. 
More recently, a sulphated derivative of the latter in the form of aluminium hydroxyphosphate sulphate has been 
used as a single component of an adjuvant system against human papilloma virus (HPV)9. Typically, the adsorp-
tive capacity of an ABA to its antigen, dictates its choice in studies of adjuvanticity. In this respect, the choice of 
adjuvant is selected according to its zeta potential or surface charge1 of which Alhydrogel® is positively charged 
at neutral pH and suitable for adsorption to negatively charged antigens, conversely to negatively charged partic-
ulates of Adju-Phos® 1,10. Ovalbumin is frequently used as a model protein antigen in experimental vaccine for-
mulations and owing to its number of side-chain carboxyl groups, possesses a net negative charge1,3,10,11. As such, 
Alhydrogel® continues to predominate as the clinically relevant adjuvant of choice in these studies.
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Few studies have employed direct comparative assessments of the physicochemical properties of clinically 
used ABA formulations with their resultant cellular uptake. Of those studies performed, Flarend and co-workers 
(1997) revealed the same biodistribution of 26Al labelled Alhydrogel® and Adju-Phos® adjuvants, when injected 
intramuscularly (i.m.) in New Zealand White rabbits12. Mass spectrometry analyses of digested tissues identified 
higher aluminium concentrations in the kidneys with the lowest concentration found in the brain. The dissolu-
tion of Adju-Phos® however, was found to be more rapid than that for Alhydrogel® with higher 26Al concentra-
tions noted in the surrounding tissues, probably owing to the amorphous nature of the former12. Whilst elevated 
26Al concentrations were found in both urine and tissue samples of those rabbits injected i.m. with Adju-Phos®, 
qualitative data pertaining to their retention and in vivo localisation through for example, histological staining 
methods, were not fully addressed in this study12.
More recently, the factors affecting the adsorption of Alhydrogel® and Adju-Phos® to their protein antigen 
have been considered in simulated vaccine formulations13. Interestingly, Alhydrogel® was found to possess a 
greater adsorptive capacity to its conversely negatively charged protein antigen, in comparison to Adju-Phos®. 
The authors noted that the capacity of Alhydrogel® to adsorb to protein antigens via ligand exchange in addition 
to electrostatic forces of attraction, explained the greater adsorptive capacity of the adjuvant13. Upon the admin-
istration of either adjuvant into the injection site however, the physiological milieu encountered is of far greater 
complexity than that of a vaccine formulation4. Weak electrostatic forces of attraction between ABAs and anti-
gens result in the rapid dissolution of the antigen in muscle interstitial fluid (MIF)4. The resultant species formed 
including the free antigen, free particulates of the ABA, particulate ABAs co-adsorbed to the antigen and the 
soluble species of aluminium, Al3+(aq)4 are crucial determinants of the resultant immune response4,13–15. As such, 
establishing the potential routes of cellular uptake and subsequent trafficking of these immune agonists through 
draining lymph nodes2, will shed light on their ability to potentiate the immune response, at sites distant to the 
injection site4,10.
Until recently, the unequivocal cellular uptake of ABA had remained elusive, whereby lumogallion 
[4-chloro-3-(2,4-dihydroxyphenylazo)-2-hydroxybenzene-1-sulphonic acid] was found to act as a selective 
molecular probe for aluminium16. The use of lumogallion has demonstrated the unequivocal identification of 
aluminium oxyhydroxide-based adjuvant formulations, including Alhydrogel® within a monocytic T helper 1 
(THP-1) cell line16 and was hence used herein for the unequivocal identification of aluminium. All pathways of 
endocytosis result in the cellular internalisation of ABA particles via the various routes through cell membranes, 
ultimately resulting in their presence within lysosomal compartments in cell cytosol17.
Phagocytosis is one of the most recognised pathways that governs the cellular internalisation and subsequent 
degradation of micron-sized particulates of ABAs, through the molecular process of autophagy17,18. In the latter 
stages of autophagy and most notably for macroautophagy19, the maturation of autophagosomes into autolyso-
somes acidifies the resultant vesicular compartments formed to approximately pH 4.0 to 4.518. This results in the 
degradation of internalised particulates of the ABA, thereby releasing Al3+(aq) into cell cytosol4,17,18. The release 
of the enzyme cathepsin B as an endogenous danger signal, in combination with the degradative products of 
ABAs as damage associated molecular patterns (DAMPs) are thereby suggested to trigger localised inflamma-
tion at the injection site20. Current understanding of the mechanisms of action of ABA have focused upon the 
adsorptive capacity of adjuvants in enhancing delivery of the antigen to antigen presenting cells10,21, activation 
of inflammasome multi-protein complexes3,22 and the release of pro-inflammatory cytokines1,10,23 polarising TH2 
immune responses1,2,10,22. In the absence of data following the cellular trafficking and fate of the aluminium adju-
vant component of a vaccine, their resultant effects underlying their immunostimulatory properties, remain to be 
elucidated. Furthermore, the continued use of equivocal methods for the identification of aluminium including 
the use of the fluorophore morin in the absence of appropriate controls24, is likely to give misleading information 
on the cellular fate of label-free aluminium adjuvants in human vaccinations.
Herein, we draw the direct comparative assessment of the physicochemical factors affecting the unequivocal 
cellular uptake of the clinically relevant Alhydrogel® and Adju-Phos® adjuvants. Furthermore, the cellular fate of 
the chemically different adjuvants were established in a relevant in vitro T helper 1 (THP-1) cell model of vacci-
nation. Whilst the term ‘alum’ refers to potassium aluminium sulphate (KAl(SO4)2·12H2O), its use is widespread 
within the literature. As such, ‘alum’ is often used incorrectly to describe all variations of ABA8. ABA are neither 
chemically, physically nor biologically equivalent and differ significantly from non-aluminium adjuvants such as 
silica or uric acid. In this respect, we additionally investigated the physicochemical properties including particle 
size and charge of an experimental crystalline magnesium hydroxide and amorphous aluminium hydroxycar-
bonate adjuvant, Imject™ Alum. Taken collectively, our results support the migratory capabilities of ABA as 
potential drivers of immunopotentiation, in vivo.
Results
Zeta potential characterisation of aluminium adjuvants within R10 culture medium. To 
investigate any potential interactions occurring at the surface interface of Alhydrogel® and Adju-Phos® adju-
vants, each was introduced into R10 culture medium and their zeta potential measured. The surface potential 
of both adjuvant formulations were found equivalent following initial administration into culture medium 
(− 12.88 ± 1.11 and  − 13.56 ± 1.14 mV, respectively, P > 0.1) and remained stable over 24 h (see Supplementary Fig. 1). 
The zeta potential values were found significantly dissimilar to those obtained for the vaccine preparations (see 
Supplementary Table 1), although the difference was more pronounced for positively charged Alhydrogel® 
(P < 0.01).
Particle size characterisation of aluminium adjuvants within R10 culture medium via dynamic 
light scattering, selective filtration and graphite furnace atomic absorption spectroscopy. To 
assess the impact of protein adsorption upon the size of adjuvant particles within biological media, dynamic 
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light scattering (DLS) was used in conjunction with selective filtration and transversely heated graphite furnace 
atomic absorption spectroscopy (TH-GFAAS). The latter method provided data regarding the abundance of 
discrete populations within such polydisperse solutions. Samples of R10 medium inoculated with adjuvanted 
vaccine preparations produced exclusively monomodal intensity distributions in which the majority of particles 
formed micron-sized aggregates. The median size of Alhydrogel® aggregates continued to increase over a 24 h 
incubation period (817.0 ± 19.0 to 1343.0 ± 46.0 nm over 24 h), although this was only significant over the first 
hour of exposure to culture medium indicating that the particles had reached their maximum size shortly after 
introduction (Fig. 1a) (P < 0.01). Indeed, the aluminium recovery between the 0.25 and 2.7 μ m size exclusion 
boundaries represented that with the highest magnitude and exhibited a marginal increase over the first hour of 
incubation (Fig. 1c) (87.1 ± 1.3 and 97.1 ± 2.4% respectively). DLS, however, failed to accurately detect the aggre-
gation occurring following 24 h exposure to R10 medium, as demonstrated by the marked increase in aluminium 
recovery observed > 5.6 μ m (Fig. 2a).
Adju-Phos® particulates while larger demonstrated a gradual reduction in median size over 24 h (2283.0 ± 62.0 
to 1760.0 ± 52.0 nm), which suggested that disaggregation was occurring within the samples over the course of 
the experiment (Fig. 1b). However, the highest recovery of aluminium was detected in the filtrates representing 
particles > 5.6 μ m and this abundance only increased over the duration of the experiment (Fig. 2b) (52.5 ± 2.0 
to 79.8 ± 5.0%). The greater sedimentation rate of larger particles can result in their non-detection via DLS and 
hence may explain the discrepancies between the results generated by these two different methodologies.
Transmission electron microscopy of aluminium adjuvants within R10 culture medium. In order 
to confirm the presence of larger adjuvant aggregates unable to be accurately measured by DLS, transmission elec-
tron microscopy (TEM) was performed upon vaccine preparations exposed to R10 medium at 0 h. Alhydrogel® 
particulates ranged from ca 1.2–2.0 μ m and were therefore found to be in close agreement with those obtained 
via DLS and selective filtration. The majority of particles identified were found surrounded by an extensive pro-
tein corona, which approximately tripled the size of those entities observed (Fig. 3a,b). Conversely, Adju-Phos® 
particulates were typically much larger in size than those detected via DLS although coronal formation was less 
extensive, and hence was found to lesser impact upon protein adsorption upon the size of those resultant com-
plexes formed (Fig. 3c,d).
The cytotoxicity of aluminium adjuvants in a monocytic T helper 1 cell line. The assessment of cel-
lular toxicity was performed over 24 h using T helper 1 (THP-1) cells of a monocytic lineage. As a phagocytic cell 
line, THP-1 cells provide an excellent model to investigate phagocytosis of ABA, used in previous studies to assess 
adjuvanticity in cellular models of vaccination16,18,25. Singular treatments of Alhydrogel® where concentrations 
Figure 1. Size distributions of Alhydrogel® (A) and Adju-Phos® (B) in R10 medium following 0, 1 and 24 h 
incubation (37 °C). Box plots are representative of the interquartile range of the data while blue dashed lines 
indicate the maxima and minima. Orange crosses indicate Z-average cumulant size values (nm) while light blue 
crosses represent the median peak size value (nm). Error bars represent the ± SE of the measurement where n = 5.
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of Al ≤ 25.0 μ g/mL, did not facilitate a considerable reduction in cell viability following a 24 h exposure regime, 
as demonstrated by the low cellular mortality exhibited by these groups (Fig. 4) (< 10.0%, P > 0.1 relative to the 
control group). However, a considerable elevation in cellular mortality was observed when the concentration of 
aluminium was increased to 100.0 μ g/mL (20.3 ± 7.9%, P < 0.05). Alhydrogel® was therefore found to be moder-
ately cytotoxic to THP-1 cells.
By contrast, treatments of Adju-Phos® induced a substantially greater level of cytotoxicity at lower concen-
trations of the adjuvant (Fig. 4). Cells treated with 2.5 μ g/mL of the adjuvant induced a 29.9 ± 2.7% reduction 
in cell viability over a 24 h exposure period (P < 0.05 relative to the control). This level of cellular mortality was 
considered moderately cytotoxic and the abundance of non-viable monocytes continued to increase as the treat-
ment dose was raised reaching ca 50.0% at 100.0 μ g/mL. The level of cellular mortality, was hence considered to 
be above the moderate-toxicity threshold, above concentrations of 25.0 μ g/mL of Adju-Phos®.
The assessment of the cellular uptake of an aluminium oxyhydroxide-based adjuvant, via flu-
orescence microscopy. Autofluorescence analyses of THP-1 cells was assessed via analysis of 2 μ m thick 
re-hydrated agar-paraffin cell sections in the absence of the fluor, lumogallion. No detectable autofluorescence 
signal was observed from THP-1 cells whether co-cultured in the absence or presence of an ABA. Native THP-1 
cells cultured in the presence of R10 medium only and stained with lumogallion for 24 h, produced a dull orange/
brown fluorescence under the lumogallion fluorescence channel (see Supplementary Fig. 2). Counter-staining 
with 4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI), confirmed the presence of cells and specifically 
cell nuclei, as observed by a blue fluorescence emission. Merging of the fluorescence channels with the bright 
field image, revealed a dull orange/brown fluorescence contained exclusively within the cytosol of THP-1 cells. 
Extracellular fluorescence through either the lumogallion or DAPI fluorescence channel was not observed for 
native cells.
In order to investigate the potential cellular uptake of increasing concentrations of Alhydrogel®, THP-1 cells 
were co-cultured in the presence of 2.5, 25.0, 50.0 or 100.0 μ g/mL of the adjuvant for 24 h (see Supplementary 
Fig. 3). THP-1 cells co-cultured in the presence of 2.5 μ g/mL Alhydrogel® and stained with lumogallion for 24 h, 
revealed bright punctuate fluorescence at their periphery (Fig. 5a). Overlaying of the DAPI fluorescence and light 
channels confirmed that lumogallion fluorescence of the ABA was contained solely within cell cytosol. THP-1 
cells co-cultured with 25.0 μ g/mL Alhydrogel® produced clear orange fluorescence in the form of spherical 
particulate-like structures that were found to be heavily loaded in cytosolic compartments (Fig. 5b). In addition, 
Figure 2. Recovery of Al (%) following selective filtration of Alhydrogel® (A) and Adju-Phos® (B) after 0, 1 
and 24 h incubation in R10 medium (37 °C). Error bars represent the %RSD of the measurement where n = 5. 
Statistical significance not shown.
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all cells identified by DAPI fluorescence, confirmed the presence of internalised lumogallion-positive particu-
lates. As with cells co-cultured in the presence of 2.5 μ g/mL of the ABA, minimal traces of extracellular adjuvant 
material were observed.
For cells co-cultured in the presence of 50.0 μ g/mL Alhydrogel®, merging of fluorescence and light channels 
revealed heavy loading of lumogallion-positive particulate-like structures within the minimal cytoplasmic space 
Figure 3. Electron micrographs depicting the morphology of ABA particulates in the presence of R10 
culture medium. (a,b) Alhydrogel® (0.25 mg/mL Al) following 0 h incubation in R10 medium. Magnification 
X 30 K, scale bars 1 μ m. (c–d) Adju-Phos® (0.25 mg/mL Al) following 0 h incubation in R10 medium. 
Magnification X 10 K and X 25 K, scale bars 2 and 1 μ m, respectively.
Figure 4. The % mortality of THP-1 cells upon exposure to various concentrations of aluminium 
adjuvants. Purple and green bars represent Alhydrogel® and Adju-Phos® respectively. The abbreviations ST, T, 
MT & NT represent the phrases severe toxicity, toxicity, moderate toxicity and null toxicity respectively. Error 
bars are representative of ± SD of 3 individual replicates and statistical significance is shown between treatments 
and respective control groups. Toxicity boundaries were adapted from Eidi et al.24.
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of THP-1 cells (Fig. 5c). Extracellular lumogallion fluorescence was observed for cells co-cultured in the presence 
of 50.0 and 100.0 μ g/mL Alhydrogel®. Interestingly, cells co-cultured at the highest concentration of the ABA 
(Fig. 5d) revealed the greatest cytoplasmic loading of lumogallion fluorescent particulates. Furthermore, only 
at the highest concentration of the ABA were fluorescent particulates found adsorbed to the plasma membrane 
of THP-1 cells, as revealed by overlaying the bright field image (Fig. 5d). Minimal variation in the size of intra-
cellular particulates of Alhydrogel® was found upon co-culture with THP-1 cells (see Supplementary Table 2), 
of which measurements across all concentrations produced an average outer diameter of 0.96 ± 0.19 μ m 
(mean ± SD, n = 340).
Comparative assessment of the cellular uptake of an aluminium hydroxyphosphate-based 
adjuvant formulation. For cells co-cultured in the presence of 2.5–100.0 μ g/mL of an amorphous alumin-
ium hydroxyphosphate-based Adju-Phos® adjuvant, a bright orange fluorescence was observed at the periphery 
of cells (see Supplementary Fig. 4). Merging of the lumogallion, DAPI and light channels revealed that particu-
lates of the adjuvant were dispersed exclusively throughout the cell cytosol (Fig. 6). Adju-Phos® particulates as 
highlighted by lumogallion fluorescence (Fig. 6), were found to be more difficult to distinguish in comparison 
to cells co-cultured with Alhydrogel® (Fig. 5). Whilst the cellular internalisation of Adju-Phos® within the cyto-
plasm of THP-1 cells was highlighted via lumogallion staining, the uptake of particulates was found to be less well 
pronounced at the highest concentrations of 50.0 and 100.0 μ g/mL (Fig. 6d) of the adjuvant. Internalised par-
ticulates of Adju-Phos® appeared larger than those of Alhydrogel® and their size remained consistent across all 
concentrations of the ABA investigated, with an average outer diameter of 1.31 ± 0.22 μ m (mean ± SD, n = 137) 
(see Supplementary Table 2).
Extracellular deposits of both amorphous and lumogallion-reactive Adju-Phos® were readily identified at 
every adjuvant concentration investigated. Interestingly, counterstaining with the nucleic-reactive dye, DAPI, 
revealed that at concentrations as low as 2.5 μ g/mL of Adju-Phos®, extracellular genetic material was observed 
(see Supplementary Fig. 5). No correlation could be drawn however, between the proportions of intact versus 
Figure 5. Representative lumogallion staining of agar-paraffin embedded (2 μ m sections) THP-1 cells co-
cultured with (a) 2.5, (b) 25.0, (c) 50.0 or (d) 100.0 μ g/mL Alhydrogel® (Brenntag Biosector, Denmark). Cell 
sections were incubated for 24 h in 100 μ M lumogallion, 50 mM PIPES, pH 7.4. Slides were mounted with 
ProLong® Gold Antifade Reagent with DAPI. All images depict lumogallion staining (orange) overlaid with 
DAPI-staining (blue). Magnified inserts show close-ups of individual cells with the light channel overlaid. White 
arrows highlight both individual and distinguishable adjuvant particles. Magnification X 1000, scale bars: 20 μ m.
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fragmented cell nuclei upon an increasing adjuvant concentration whereas cell nuclei were found to remain intact 
at all concentrations analysed for Alhydrogel® (see Supplementary Fig. 3).
Assessment of the cellular internalisation of an experimental aluminium hydroxycarbonate 
and magnesium hydroxide-based adjuvant. The extracellular uptake of Imject™ Alum was found to be 
less pronounced at 2.5 μ g/mL in comparison to the clinically used ABAs, as revealed through the lumogallion flu-
orescence channel (Fig. 7a). Those internalised particulates observed were also found to vary considerably in size 
with an average outer diameter of 2.11 ± 0.78 μ m (mean ± SD, n = 17) (see Supplementary Table 2). Cellular inter-
nalisation of Imject™ Alum was also identified at 25.0 and 50.0 μ g/mL, as identified by lumogallion fluorescence 
(Fig. 7b,c). The cellular uptake of Imject™ Alum was less pronounced at 100.0 μ g/mL however, overlaying of the 
bright field image confirmed that those particulates internalised were confined within the cell cytoplasm of THP-1 
cells (Fig. 7d). In spite of modifications in the agar-paraffin embedding protocol employed (see Supplementary 
methods), extracellular material remained identifiable via lumogallion fluorescence at 100.0 μ g/mL 
of the ABA (see Supplementary Fig. 6). Extracellular genetic material was not observed at any adjuvant concen-
tration analysed. Measurements of the size of internalised particles of Imject™ Alum were found to vary consider-
ably from cell to cell under all treatment conditions with an average outer diameter of 1.90 ± 0.81 μ m (mean ± SD, 
n = 93) (see Supplementary Table 2).
Transmission electron microscopy reveals morphological variations of internalised aluminium 
based adjuvant particulates. In order to reveal potential morphological variations between internalised 
particulates of the differing ABA investigated, 50.0 μ g/mL of each was co-cultured for 24 h with THP-1 cells and 
analysed by TEM16. Negative staining of native THP-1 cells cultured in R10 medium only, revealed the absence 
of internalised particulate material and a clear distinction between a granular cell cytosol and positively stained 
cell nuclei (Fig. 8a,e,i). TEM of cells co-cultured in the presence of Alhydrogel® confirmed the internalisation 
of adjuvant particles (Fig. 5), of which electron dense particulates were found contained within the cytoplasm 
only (Fig. 8b). Higher magnifications revealed needle-like crystalline rods contained within clear cellular vesicles 
Figure 6. Representative lumogallion staining of agar-paraffin embedded (2 μ m sections) THP-1 cells co-
cultured with (a) 2.5, (b) 25, (c) 50 or (d) 100 μ g/mL Adju-Phos® (Brenntag Biosector, Denmark). Cell sections 
were incubated for 24 h in 100 μ M lumogallion, 50 mM PIPES, pH 7.4. Slides were mounted with ProLong® 
Gold Antifade Reagent with DAPI. All images depict lumogallion staining (orange) overlaid with DAPI-staining 
(blue). Magnified inserts show close-ups of individual cells with the light channel overlaid. White arrows 
highlight both individual and distinguishable adjuvant particles. Magnification X 1000, scale bars: 20 μ m.
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(Fig. 8f,j). Particle size measurements of internalised aggregates of Alhydrogel® (see Supplementary Table 2) 
were found to closely correspond with those deposits detected via fluorescence microscopy, with an average 
outer diameter of 0.91 ± 0.14 μ m (mean ± SD, n = 17). Owing to the needle-like morphology of those intracellular 
shaped crystals observed (Fig. 8j), their dimensions could be determined of which single crystals produced an 
average width of 8.2 ± 1.2 nm, of 54.1 ± 7.7 nm in length (mean ± SD, n = 17).
THP-1 cells co-cultured in the presence of Adju-Phos® revealed positively stained amorphous aggregates in 
apparent cellular vesicles with an average size of 1.09 ± 0.25 μ m (mean ± SD, n = 17) (see Supplementary Table 2) 
(Fig. 8c). Higher magnifications demonstrated that internalised aggregates of the adjuvant were constituted of 
negatively stained plate-like structures with an outer diameter of 15.0 ± 2.9 nm (mean ± SD, n = 17) (Fig. 8g,k). 
Intracellular particulates of Adju-Phos® were found more greatly dispersed throughout the cytoplasm of THP-1 
cells, than those co-cultured in the presence of Alhydrogel®. Furthermore, a loss in integrity of the cell cyto-
plasm for cells co-cultured in the presence of Adju-Phos® was revealed, in comparison to cells co-cultured in the 
absence (Fig. 8a,e,i) or presence (Fig. 8b,f,j) of Alhydrogel®.
THP-1 cells co-cultured with 50.0 μ g/mL Imject™ Alum contained large and amorphous particulates within 
cell cytosol only, with an average outer diameter of 1.21 ± 0.27 μ m (mean ± SD, n = 3). Dense positive staining 
was observed for internalised particles of the adjuvant, with magnifications of X 30 K and higher revealing densely 
stacked and negatively stained plates, with an approximate outer diameter of 67.9 ± 10.8 nm (mean ± SD, n = 17). 
Minimal losses in the integrity of the cell cytoplasm was found, as for cells co-cultured in the absence or presence 
of Alhydrogel®. Higher magnifications of X 60 K, revealed a second needle-like crystalline morphology of inter-
nalised particulates of Imject™ Alum within the cytoplasm of THP-1 cells (Fig. 8l). The electron micrographs 
obtained therefore depicted two distinct particulate morphologies, which suggested their co-existence in the ABA 
formulation, or their potential degradation in the cytosolic compartment of THP-1 cells.
Discussion
We have drawn the direct comparative assessment of the physicochemical properties and biological factors under-
lying the unequivocal cellular uptake and adjuvanticity of clinically relevant and experimental ABA formulations, 
Figure 7. Representative lumogallion staining of agar-paraffin embedded (2 μ m sections) THP-1 cells co-
cultured with (a) 2.5, (b) 25, (c) 50 or (d) 100 μ g/mL Imject™ Alum (Thermo Scientific). Cell sections were 
incubated for 24 h in 100 μ M lumogallion, 50 mM PIPES, pH 7.4. Slides were mounted with ProLong® Gold 
Antifade Reagent with DAPI. All images depict lumogallion staining (orange) overlaid with DAPI-staining 
(blue). Magnified inserts show close-ups of individual cells with the light channel overlaid. White arrows 
highlight both individual and distinguishable adjuvant particles. Magnification X 1000, scale bars: 20 μ m.
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in a relevant THP-1 cell model of vaccination16,18,25. Herein, we have demonstrated that of the most commonly 
used ABA in clinically approved vaccinations, neither aluminium oxyhydroxide (Alhydrogel®) nor aluminium 
hydroxyphosphate (Adju-Phos®) are equivalent in their physico-chemistry nor in their biological reactivity. Our 
results continue to raise concern26 over use of the experimental and chemically different, aluminium hydrox-
ycarbonate and magnesium hydroxide based Imject™ Alum formulation27, as the model adjuvant of choice in 
the study of clinical vaccination. Furthermore Imject™ Alum has been shown to elicit weaker humoral TH2 
immune responses via diminished IgG antibody production and reduced pro-inflammatory cytokine release ver-
sus Alhydrogel®, in a nitrophenol-chicken-gamma-globulin hapten carrier antigen (NP-CGG) model of murine 
vaccination26.
Striking differences in separate reports of the immunomodulatory properties of ABA have been linked to 
variations in adjuvant formulation and their respective dose3,10. For example, the important discovery of the 
multiprotein Nalp3 inflammasome22 is now regarded as playing a contributory3 rather than a crucial role in the 
adjuvanticity of ABA through driving inflammation through IL-1β and IL-18 release22,28. As such, our initial 
efforts were focused upon establishing the physicochemical properties of the clinically relevant Alhydrogel® and 
Adju-Phos® adjuvants, with respect to their particle size and surface zeta potential or charge, in a proteinaceous 
R10 cell culture medium, modelling MIF at the injection site29,30.
It was observed that whilst Alhydrogel® was found positively charged conversely to negatively charged 
Adju-Phos® in simulated 0.9% NaCl vaccine diluent, once introduced into R10, both formulations possessed a 
steady net negative charge. Complementary analyses via TEM at 0 h confirmed the rapid formation of an exten-
sive protein corona in R10 formed around particulates of each ABA thereby explaining the masked and equiv-
alent surface charges in vitro (Fig. 3). Hence the rapid dissolution of the antigen from its ABA upon competing 
interactions with interstitial proteins31, may explain reported discrepancies in the depot effect, via gradual and 
sustained antigen released10.
Particle sizes of Alhydrogel® in R10 by DLS showed the gradual aggregation of adjuvant, with particles present 
in the micron range of ca 1.4 μ m, following 24 h, in contrast to Adju-Phos® of which particles were observed to 
disaggregate from 2.2 to ca 1.8 μ m (Fig. 1). Due to the rapid molecular process of phagocytosis in which particles 
are typically engulfed in fewer than twenty minutes32, Alhydrogel® is more predisposed to lie in the optimal size 
range of phagocytosis from 0.5–5.0 μ m33, in contrast to Adju-Phos® over the first 24 h. The latter is most likely 
only internalised by phagocytic entry at the earliest time points as approximately 80% of particulates lie outside 
of phagocytic range by 1 h, increasing to 97% by 24 h.
Figure 8. Representative electron micrographs from TEM of Spurr resin-sectioned (100 nm sections) native 
THP-1 cells (a,e,i), THP-1 cells co-cultured with 50 μ g/mL Alhydrogel® (24 h) (b,f,j) and 50 μ g/mL Adju-Phos® 
(Brenntag Biosector, Denmark) adjuvant (24 h) (c,g,k) and 50 μ g/mL Imject™ Alum (Pierce, Thermo Scientific) 
adjuvant (24 h) (d,h,l). Cell resin-sections were stained for 20 min with 2% ethanolic uranyl acetate, rinsed with 
30% ethanol followed by ultrapure water and finally allowed 24 h drying time prior to analysis via TEM. Inserts 
show close-ups of intracellular adjuvant particles contained within vesicle-like structures and the red arrows 
highlight their presence within the respective cell images. Magnification and scale bars: (a–c) X 8 K, 5 μ m,  
(d) X 10 K, 2 μ m, (e) X 15 K, 2 μ m, (f–h) X 30 K, 1 μ m, (i) X 30 K, 1 μ m and (j–l) X 60 K, 0.5 μ m, respectively.
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Monocytes are typically recruited to the injection site following 24 h from initial administration of an ABA34 
and subsequently dominate phagocytic clearance of particulates over early infiltrating neutrophils35, in the size 
range of 0.5–5 μ m33. Taken collectively, our results therefore predict that Adju-Phos® is most likely phagocytosed 
by neutrophils over Alhydrogel® adjuvanted vaccines, whereby phagocytic clearance is governed by monocytes 
at the injection site. The enhanced phagocytosis of Adju-Phos® by infiltrating neutrophils over the earliest time 
points following vaccination may only be speculated at present, in the absence of in vitro data demonstrating such 
unequivocal cellular uptake.
Whilst the infiltration of macrophages at the injection site seven days post-vaccination would likely govern the 
phagocytic clearance of particulate ABA immune agonists at the injection site4,17,34, all aforementioned cell types 
may act as antigen presenting cells (APCs)36, capable of triggering adaptive immune responses10. Therefore we 
next addressed the unequivocal cellular uptake of ABA using lumogallion as an established fluorescent molecular 
probe for the detection of intracellular aluminium16,17,25,37.
Regardless of the ABA investigated intracellular adjuvant particulates were only found localised in the cyto-
plasm of THP-1 cells. Alhydrogel® was found internalised at every concentration investigated (Fig. 5), whereas 
for both Adju-Phos® (Fig. 6) and Imject™ Alum (Fig. 7), internalisation was less pronounced at concentrations at 
or exceeding 50.0 μ g/mL of the respective adjuvant. At ABA concentrations where the cellular internalisation of 
particulates was always observed (2.5 to 25.0 μ g/mL), Alhydrogel® exhibited the greatest cytoplasmic particulate 
loading. Furthermore Alhydrogel® was the only ABA investigated that was found co-adsorbed to the plasma 
membrane of cells where near complete loading of the cytoplasm was observed at 100.0 μ g/mL of the adjuvant. 
Intracellular ABA particulates across all ABA concentrations investigated, revealed that particulates of Imject™ 
Alum were greatest and most variable in size followed by Adju-Phos® and finally Alhydrogel® at ca 1.9, 1.3 and 
1.0 μ m, respectively (see Supplementary Table 2).
Intracellular particulates of Adju-Phos® were found to be most heterogeneous, in which the diffuse lumogal-
lion staining observed was likely a result of the ease of solubilisation of the amorphous adjuvant. Strikingly, 
only cells co-cultured with Adju-Phos® were found to release genetic material into the extracellular milieu at 
concentrations as low as 2.5 μ g/mL of the adjuvant (see Supplementary Fig. 5). Adju-Phos® was also found more 
cytotoxic to THP-1 cells than Alhydrogel®, of which less than 50% of cells were found viable at the highest con-
centration of the adjuvant analysed at 100.0 μ g/mL (Fig. 4). In contrast, Alhydrogel® was only found moderately 
cytotoxic to cells above the control group at 100.0 μ g/mL. The extracellular release of DNA from dying cells has 
been found to enhance the adjuvanticity of ABA as DAMPs that activate the Nalp3 inflammasome2,38. Therefore, 
the reduced cellular uptake of amorphous Adju-Phos® and its enhanced cytotoxicity at the injection site spec-
ulatively through Al3+(aq) release4,17, in comparison to semi-crystalline Alhydrogel® 8,27, may act to mediate its 
adjuvanticity by an alternative cellular pathway of immunopotentiation.
Finally TEM of cells co-cultured with ABA was performed in order to uncover the potential morphological 
variations of those intracellular particulates revealed by fluorescence microscopy. TEM revealed the same trend in 
intracellular ABA particulate sizes (Imj > Adj > Alh) with smaller particle sizes attributed to thinner sectioning at 
100 nm necessary for TEM16. As with fluorescence microscopy, particulates of ABA were solely found contained 
within the cytoplasm only of THP-1 cells (Fig. 8). Semi-crystalline rods of Alhydrogel® of length and width 
54.1 ± 7.7 and 8.2 ± 1.2 nm (mean ± SD, n = 17) respectively, were found readily internalised within vesicular-like 
structures within THP-1 cells. Measurements of intracellular partially ordered needles of Alhydrogel® were found 
to constitute aggregates of primary particles of 4.5 × 2.2 × 10.0 nm known for structurally related boehmite 
preparations as confirmed by the complementary use of X-ray crystallography and Fourier transform infrared 
spectroscopy, respectively8.
Intracellular and individual plate-like structures of Adju-Phos® were found surprisingly smaller at 
15.0 ± 2.9 nm than single needles of Alhydrogel®, that whilst contained in endosomal compartments, lacked 
membrane enclosure. In support of those findings from fluorescence microscopy, the smaller particle sizes 
observed demonstrated the ease of dissolution of Adju-Phos® in acidified cellular compartments and as such 
may also explain greater distribution of amorphous particulates of the adjuvant throughout THP-1 cell cytosol. 
Furthermore, a loss of integrity of the plasma membrane was observed for cells co-cultured with Adju-Phos® 
thereby explaining the release of genetic material38 through cytotoxicity and potential cellular lysis. Comparative 
analyses of the experimental Imject™ Alum formulation via TEM revealed the largest of all single intracellular 
ABA particulates of 67.9 ± 10.8 nm, in which negatively stained plates were observed stacked densely into amor-
phous aggregates. Needle-like crystals were also observed of crystalline magnesium hydroxide or speculatively 
additional breakdown products of the adjuvant.
Overall TEM provided insight for the first time of the capability of THP-1 cells to internalise multiple ABA 
morphologies most notably through phagocytosis resulting in their presence in autolysosomal vesicles16–18,25 as 
was especially prevalent for Alhydrogel®. In spite of Imject™ Alum demonstrating the largest and most hetero-
geneous of intracellular ABA particulates of those formulations investigated, no loss in the cytoplasmic integrity 
was observed unlike those cells co-cultured in the presence of Adju-Phos®. Phagocytosis is regulated through 
reorganisation of the actin cytoskeleton and is necessary to allow for the cellular uptake of particulate material39. 
This mechanism of cellular uptake is known to be of detriment to the cell however, due to formation of large pores 
in the plasma membrane39. Taken collectively our results thereby support that the release of extracellular DNA 
and the cytotoxicity of Adju-Phos® may be additionally governed by the release of Al3+(aq) at the injection site4,17.
In conclusion, our results demonstrate through minimal cytotoxicity and high cytoplasmic loading that 
Alhydrogel® as the most commonly used ABA in clinically approved vaccinations is most pre-disposed to migra-
tion away from the injection site through migratory phagocytic cell lineages. It is known that monocytes are capa-
ble of differentiating into either macrophagic or dendritic cell types36 and both have subsequently been linked to 
the presence of increased MHCII-positive DCs at the injection site, seven days following vaccination34,35. As such, 
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migratory APCs including monocytes containing the internalised antigen may enter lymph nodes via draining 
through high endothelial venules (HEVs)36.
Bone marrow derived dendritic cells (BMDCs), have been previously utilised to further understanding of 
the biological mechanisms of action of ABA21. As professional antigen APCs representing the innate arm of 
the immune system, DCs are pivotal in driving an adaptive immune response in vaccination10. ABA have been 
suggested to promote an abortive non-endocytic pathway of the antigen only across DC membranes through 
lipid rearrangement40. Therefore, BMDCs are not predicted to phagocytose ABA. Regardless of whether ABA are 
phagocytosed by BMDCs or other APCs, the migration of ABA loaded monocytes to sites distant to the injec-
tion site, would establish their enhanced transport to resting DCs. Through subsequent activation of the Nalp3 
inflammasome10,22 and enhanced MHCII-presented antigen site expression upon the surface of activated DCs21, 
an enhanced engagement of naïve CD4+ T cells takes place. The subsequent stimulation of T-cells through anti-
gen presentation to resident B-cells, triggers plasma cell formation and the production of antibodies through TH2 
humoral immune responses, effectively combatting the target antigen2,10,23,36.
Through in vitro cellular modelling, our results further shed light on the capacity of ABA to deposit at sites 
distant to the injection site as has been suggested in macrophagic myofasciitis (MMF), whereby aluminium is 
proposed to translocate through draining lymph nodes to distant organs24,41.
Methods
Dynamic light scattering and zeta potential analysis. Particle size and zeta potential analysis was 
performed using a Zetasizer Nano ZS (Malvern Instruments, UK) equipped with a red laser (633 nm) whose 
detection ranges for each method were 0.6 nm–6.0 μ m and 3.0 nm–10 μ m respectively. Briefly, vaccine prepara-
tions were introduced into R10 medium at 37 °C and analysed after incubation periods of 0, 1 and 24 h. The final 
concentration of aluminium within the R10 medium post vaccine administration was ca 130 μ g/mL. A total of 
five measurements were made per sample replicate (n = 5) and the average of these was used to derive size distri-
bution and zeta potential values.
Size exclusion filtration of aluminium adjuvants. Size exclusion of samples was performed using 
syringe filtration through a variety of membranes, which were sterilised via exposure to ethylene oxide or 
γ radiation prior to purchase (see Supplementary Table 3). PTFE membranes were treated with 70% v/v ethanol 
prior to use to achieve a hydrophilic surface suitable for aqueous filtration. Membrane affinity for serum pro-
teins and aluminium was evaluated as part of method optimisation. Briefly, before each filtration step samples 
were inverted briefly in an attempt to equivalently distribute particulates. Aluminium adjuvant treatments were 
sequentially filtered through 5.6, 2.7 and 0.25 μ m, PVDF, PTFE and PVS membranes respectively, in order to 
prevent unnecessary blockage of filter membranes with smaller nominal pore sizes. Filtrates were retained for the 
analyses set out herein.
Graphite furnace atomic absorption spectroscopy of aluminium adjuvant filtrates. The protocol 
used for the quantification of aluminium within filtrates was adapted from an established method by House et al.42. 
Briefly experimental solutions and corresponding filtrates (1 mL) were acidified to 50% v/v using concentrated 
HNO3 (15.8 M, analytical grade - Fisher scientific, UK). Acidified solutions, which included negative nitric acid con-
trols, were digested using a 1800 watt MARS 6 Xpress microwave digester (CEM Corp., US) at 180 °C for 40 mins. 
Quantification of solution aluminium content was performed using an AAnalyst 600 atomic absorption spectrom-
eter complete with transversely heated graphite atomizer (THGA) and AS 800 autosampler (Perkin Elmer, UK). 
The equipment was calibrated using freshly prepared aluminium solutions in 1% HNO3 (max. 60 μ g/L Al) 
and digests were diluted in ultrapure water where appropriate prior to analysis.
THP-1 cell culture and fixation. THP-1 cells (ATCC TIB-202, LGC Standards, UK) were cultured accord-
ing to the manufacturer instructions as described in the supplementary methods online. Native THP-1 cells 
(i.e. those containing no ABA) were cultured in the presence of complete R10 medium only. Those cell treatments 
containing the ABA were co-cultured in R10 media containing a final concentration 2.5, 25.0, 50.0 or 100.0 μ g/mL 
of either Alhydrogel® (2%), Adju-Phos® (both from Brenntag Biosector, Denmark) or Imject™ Alum (Thermo 
Scientific, Pierce) for 24 h. Cell treatments for fluorescence microscopy were prepared in 96 well plates using 
ca 3 × 105 cells for each treatment condition, with a final volume of 200 μ L per well. Following 24 h incubation, 
cells were aspirated from the wells and 10.0 mL of 0.22 μ m filtered isotonic PIPES buffered saline (150 mM NaCl, 
50 mM PIPES, pH 7.4) was added to each respective pooled cell treatment. Cell treatments were subsequently 
centrifuged at 800 g at ambient temperature for 10 min and the supernatants thereafter removed.
Cells were fixed by the addition of 0.22 μ m filtered 4% w/v paraformaldehyde (4% w/v PFA, 150 mM NaCl, 
25 mM PIPES, pH 7.4), proceeded by incubation at ambient temperature for 20 min. Fixed cells were subse-
quently pelleted and washed three times in isotonic PIPES buffered saline, prior to pre-embedding in an agar 
support medium.
Cytotoxicity assay (Live/dead staining). Live/dead staining kits purchased from Life technologies, UK 
were used to measure the viability of THP-1 cells, following treatment with aluminium adjuvants. Cells from 
parent cultures were harvested, counted and seeded into 96 well plates at a final density of ca 1 × 106 cells/mL. 
Cells were treated with vaccine preparations containing 2.5, 25.0 and 100.0 μ g/mL Al and subsequently incubated 
at 37 °C under humidified CO2 conditions (5%) for 24 h. Control and treated cells were isolated from the culture 
medium via centrifugation at 300 g for 10 mins and washed three times in 1X phosphate buffered saline (PBS) 
to reduce any residual esterase activity. Cells were re-suspended in fresh PBS and applied to a non-sterile black 
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96 well fluorescence plate (100 μ L per well). The fluorescence intensity from each well was measured using a 
GloMax® -Multi+ microplate multimode reader (Promega, UK), as described in the supplementary methods.
Lumogallion staining of cell sections. Rehydrated agar-cell sections were stained by fully immersing 
slides in 250.0 mL 100 μ M lumogallion (TCI Europe N.V. Belgium) buffered in 50 mM PIPES, pH 7.4. For aut-
ofluorescence analyses of THP-1 cells, sections were placed into the same PIPES-buffer in the absence of added 
lumogallion. All sections were covered and incubated at ambient temperature in the dark for 24 h. Lumogallion 
stained cell sections were subsequently rinsed by agitation in 50 mM PIPES, pH 7.4 for 2 min, prior to rinsing for 
30 s in ultrapure water to remove excess buffer. Sections for autofluorescence were rinsed in ultrapure water only. 
The latter was performed to prevent precipitation of PIPES upon the drying of cell sections. Sections were finally 
air dried and mounted using ProLong® Gold Antifade Reagent with 4′,6-diamidino-2-phenylindole, dihydro-
chloride (DAPI) (Life Technologies, UK) prior to storing horizontally for 24 h at 4 °C.
Fluorescence microscopy. DAPI-mounted THP-1 cell sections were viewed by use of an Olympus BX50 
fluorescence microscope (mercury source). Fluorescence micrographs were obtained at X 1000 magnification 
using a X 100 Plan-Fluorite oil immersion objective (Olympus, UK) using a low auto-fluorescence immersion oil 
(Olympus immersion oil type-F). Fixed light transmission values were maintained across all respective treatment 
conditions and images obtained, using the CellD software (Olympus, Soft Imaging Solutions, GmbH) package. 
An Olympus U-MWU2 fluorescence filter cube (excitation: 300–385 nm, dichromatic: 400 nm, longpass emis-
sion filter: 420 nm) was used to assess DAPI fluorescence and for lumogallion imaging a single band pass emis-
sion filter (Chroma®, Vermont, US) was swapped into an existing U-MNIB3 fluorescence filter cube (excitation: 
470–495 nm, dichromatic mirror: 505 nm, single band pass filter: 570–630 nm). Fluorescence and light channels 
were overlaid by the use of Photoshop (Adobe systems Inc. USA).
Transmission electron microscopy (TEM). THP-1 cell blocks were embedded into Spurr-resin as previ-
ously described16 and detailed in the supplementary methods. Spurr-resin embedded agar cell blocks were sec-
tioned at 100 nm and floated onto ultrapure water. Sections were expanded using chloroform vapour and caught 
on 200 mesh, thin bar 3.05 mm copper grids (Athene, UK). Following 24 h, grids were negatively stained with 2% 
w/v uranyl acetate (UA) in 70% v/v ethanol. Briefly, grids were negatively stained in UA for 20 min, wicked and 
dipped 20 times in a large volume of 30% v/v ethanol. Grids were re-wicked after this step and rinsed by succes-
sively dipping 10 times in two changes of ultrapure water, with wicking performed between rinses. Grids were 
subsequently covered and allowed 24 h drying time, prior to analysis via TEM using a JEOL 1230 transmission 
electron microscope as described in the supplementary methods.
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